Update: Data on the responses of neurons and astrocytes to oxidative injury in the presence of insulin-like growth factor I

<p>Fig1a) Neuron viability measured as percentage of GFP positive cells cultured ± astrocytes after treatment with H2O2. N: neurons, NA: neurons + astrocytes. Names for each file refer to the related figures in the associated research article.</p> <p>Fig1b) IGF-I measured in the supernatant of neuron or astrocyte cultures treated ± with H2O2.</p> <p>Fig1c) UPDATED with additional data: pAKT levels measured in astrocytes transfected with an IGF-IR dominant negative construct (IGF-IR DN) after treatment with IGF-I.</p> <p>Fig1d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes transfected with IGF-IR DN.</p> <p>Fig2a) pAKT levels in astrocytes treated ± with PPP (picropodophyllin) after treatment with IGF-I.</p> <p>Fig2b) Neuron viability measured as percentage of GFP positive cells treated ± with PPP and H2O2.</p> <p>Fig2c) Neuron viability expressed as percentage of GFP positive cells cultured with astrocytes and treated ± with PPP and H2O2.</p> <p>Fig2d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes (both cells types from forebrain) and treated ± with PPP and H2O2.</p> <p>Fig2e) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes and treated with IGF-I, H2O2 or both.</p> <p>Fig3a) Neuron death measured as percentage of PI positive cells treated ± with IGF-I and H2O2.</p> <p>Fig3b) Astrocyte survival expressed as percentage of PI negative cells treated ± with IGF-I and H2O2.</p> <p>Fig3c) FOXO activity from astrocytes treated with IGF-I, H2O2 or both.</p> <p>Fig3d) Cell survival expressed as percentage of GFP positive cells for astrocytes transfected with wt or AKT-insensitive mutant FOXO, treated ± with IGF-Iand H2O2.</p> <p>Fig3e) pAKT levels form astrocytes treated with IGF-I I ± H2O2.</p> <p>Fig4a) Mitochondrial O2- measured in astrocytes treated ± with IGF-I and H2O2.</p> <p>Fig4b) Total ROS (reactive oxygen species) measured in astrocytes treated ± with IGF-I and H2O2.</p> <p>Fig5a) Cu/Zn SOD (superoxide dismutase) levels from astrocytes treated with IGF-I, H2O2 or both.</p> <p>Fig5b) Mn SOD levels from astrocytes treated with IGF-I, H2O2 or both.</p> <p>Fig6a) TXNIP levels from astrocytes treated with IGF-I, H2O2 or both.</p> <p>Fig6b) Cell survival from astrocytes transfected with TXNIP shRNA ± H2O2.</p> <p>Fig6c) TXNIP levels from neurons treated with IGF-I, H2O2 or both.</p> <p>Fig6d) TXNIP levels from astrocytes pre-treated with the calcium inhibitor BAPTA in the presence of IGF-I, H2O2 or both.</p> <p>Fig7a) SCF (stem cell factor) mRNA from astrocytes treated with IGF-I, H2O2 or both.</p> <p>Fig7b) Neuron viability measured as percentage of GFP positive cells treated with IGF-I, SCF or both in the presence of H2O2.</p> <p>Fig7c) pERK levels form astrocytes treated with IGF-I, SCF or both ± H2O2.</p> <p>Fig7d) SCF and IGF-I mRNA from control or MCAO (medial cerebral artery occlusion) animal cortex (contralateral or ispsilateral cortex).</p> <p>Fig7e) SCF protein levels from control or MCAO animal cortex (contralateral or ispsilateral cortex).</p> <p>Luminol) Reactive oxygen species (ROS) measurements using luminol (which detects superoxide anions)</p>